Merck doesn't have to repay La. for Vioxx; Former BMS execs in deal with prosecutors;

 @FiercePharma: Journal questions independence of key Crestor trial. Article  | Follow @FiercePharma

> Merck won the first trial over withdrawn painkiller Vioxx brought by a state trying to recoup what it paid for the former blockbuster drug. Article

> Two former Bristol-Myers Squibb executives have reached deals with U.S. prosecutors that will end their criminal fraud cases as long as they stay out of trouble. Report

> Drugmakers including King Pharmaceuticals and Johnson & Johnson won't need to register doctors or patients as part of a plan to minimize the risks of long-acting painkillers, U.S. regulators said. Report

> Soleil Securities initiated coverage on shares of Eli Lilly with a sell rating, noting that several products are set to lose their patent protection; Soleil set a price target of $28 per share. Story

> India's oldest pharmaceutical company, Alembic Ltd, is spinning off its main pharmaceutical business into a separate subsidiary company, Alembic Pharma (APL), to unlock the value of its branded formulation business. Article

Biotech News

@FierceBiotech: Bind banks $12.4M round as lead program heads into PhI. Article  | Follow @FierceBiotech

@JohnCFierce: Three doses of a Forest pain drug can't significantly outperform a placebo in Ph2 diabetes study. Article  | @JohnCFierce

> On a spree, Sanofi scoops up TargeGen in $635 million deal. Story

> Noxxon's Morich to leave in August. Item

> Calistoga banks $40 million Series C for pivotal trial work. Report

> SV Life Sciences flush with venture cash, bullish on exit deals. News

Drug Delivery News

> Start-up gains funds to test tumor-targeting tech. Item

> OctoPlus strikes delivery tech development pact with Novartis. Story

> Sosei lands deal for new nanotech platform technology. Report

> UK researchers fine tune nanogel delivery system. Article

Biomarkers News

> Survey: Use of biomarkers growing fast among drug developers. News

> CDI, Promega to collaborate on in vitro assays. Report

> Febit chops staff as it focuses on microRNA biomarker discovery. Item

Medical Device News

> Study: Medtronic insulin pump bests injections. Story

> Council mulls improvements to med device development. Report

> U of M fellows look to change how IVs are used. Item

Special Report: Top top 10 pharma cargo thefts of 2009/2010. Special Report

And Finally... Intensive control of blood sugar doesn't reduce the odds of cardiovascular disease for those with long-term type 2 diabetes who are at risk of heart problems, but it may have some other benefits, a new analysis suggests. Report